Investors in hepatitis C virus (HCV) firms went into panic mode Friday after Pharmasset Inc. dropped guanine nucleotide analogue PSI-938 from its Phase IIb QUANTUM trial after routine monitoring unveiled laboratory abnormalities associated with liver function in patients receiving the drug.